Rule2022-11740
Schedules of Controlled Substances: Placement of N-Ethylhexedrone, alpha-Pyrrolidinohexanophenone, 4-Methyl-alpha-ethylaminopentiophenone, 4′-Methyl-alpha-pyrrolidinohexiophenone, alpha-Pyrrolidinoheptaphenone, and 4′-Chloro-alpha-pyrrolidinovalerophenone in Schedule I
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 1, 2022
Effective
June 1, 2022
Issuing agencies
Justice DepartmentDrug Enforcement Administration
Abstract
By this rule, the Drug Enforcement Administration permanently places six synthetic cathinones, as identified in this rule, in schedule I of the Controlled Substances Act. These six substances are currently listed in schedule I pursuant to a temporary scheduling order. As a result of this rule, the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess) or propose to handle these six specified controlled substances will continue to apply.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 105 (Wednesday, June 1, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 105 (Wednesday, June 1, 2022)]
[Rules and Regulations]
[Pages 32996-32999]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-11740]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1308
[Docket No. DEA-495]
Schedules of Controlled Substances: Placement of N-
Ethylhexedrone, alpha-Pyrrolidinohexanophenone, 4-Methyl-alpha-
ethylaminopentiophenone, 4'-Methyl-alpha-pyrrolidinohexiophenone,
alpha-Pyrrolidinoheptaphenone, and 4'-Chloro-alpha-
pyrrolidinovalerophenone in Schedule I
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: By this rule, the Drug Enforcement Administration permanently
places six synthetic cathinones, as identified in this rule, in
schedule I of the Controlled Substances Act. These six substances are
currently listed in schedule I pursuant to a temporary scheduling
order. As a result of this rule, the regulatory controls and
administrative, civil, and criminal sanctions applicable to schedule I
controlled substances on persons who handle (manufacture, distribute,
reverse distribute, import, export, engage in research, conduct
instructional activities or chemical analysis, or possess) or propose
to handle these six specified controlled substances will continue to
apply.
DATES: Effective June 1, 2022.
FOR FURTHER INFORMATION CONTACT: Terrence L. Boos, Drug and Chemical
Evaluation Section, Diversion Control Division, Drug Enforcement
Administration; Telephone: (571) 362-8207.
SUPPLEMENTARY INFORMATION: In this rule, the Drug Enforcement
Administration (DEA) is permanently
[[Page 32997]]
scheduling the following six controlled substances, including their
optical, positional, and geometric isomers, salts, and salts of isomers
whenever the existence of such salts, isomers, and salts of isomers is
possible within the specific chemical designation, in schedule I of the
Controlled Substances Act (CSA):
<bullet> N-ethylhexedrone (other names: [alpha]-
ethylaminohexanophenone, 2-(ethylamino)-1-phenylhexan-1-one),
<bullet> alpha-pyrrolidinohexanophenone (other names: [alpha]-PHP,
[alpha]-pyrrolidinohexanophenone, 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-
one),
<bullet> 4-methyl-alpha-ethylaminopentiophenone (other names: 4-
MEAP, 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one),
<bullet> 4'-methyl-alpha-pyrrolidinohexiophenone (other names:
MPHP, 4'-methyl-alpha-pyrrolidinohexanophenone, 1-(4-methylphenyl)-2-
(pyrrolidin-1-yl)hexan-1-one),
<bullet> alpha-pyrrolidinoheptaphenone (other names: PV8, 1-phenyl-
2-(pyrrolidin-1-yl)heptan-1-one), and
<bullet> 4'-chloro-alpha-pyrrolidinovalerophenone (other names: 4-
chloro-[alpha]-PVP, 4'-chloro-[alpha]-pyrrolidinopentiophenone, 1-(4-
chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one).
Legal Authority
The CSA provides that proceedings for the issuance, amendment, or
repeal of the scheduling of any drug or other substance may be
initiated by the Attorney General: (1) On his own motion; (2) at the
request of the Secretary of the Department of Health and Human Services
(HHS); \1\ or (3) on the petition of any interested party. 21 U.S.C.
811(a). This action was initiated on the Attorney General's own motion,
as delegated to the Administrator of the Drug Enforcement
Administration (DEA), and is supported by, inter alia, a recommendation
from the Assistant Secretary for Health of HHS (Assistant Secretary)
and an evaluation of all other relevant data by DEA. The regulatory
controls and administrative, civil, and criminal sanctions for schedule
I controlled substances on any person who handles or proposes to handle
N-ethylhexedrone, [alpha]-PHP, 4-MEAP, MPHP, PV8, or 4-chloro-[alpha]-
PVP will continue to apply as a result of this action.
---------------------------------------------------------------------------
\1\ As discussed in a memorandum of understanding entered into
by the Food and Drug Administration (FDA) and the National Institute
on Drug Abuse (NIDA), FDA acts as the lead agency within HHS in
carrying out the Secretary's scheduling responsibilities under the
CSA, with the concurrence of NIDA. 50 FR 9518, Mar. 8, 1985. The
Secretary of HHS has delegated to the Assistant Secretary for Health
of HHS the authority to make domestic drug scheduling
recommendations. 58 FR 35460, July 1, 1993.
---------------------------------------------------------------------------
Background
The subject substances of this final rule are currently controlled
in schedule I of the CSA by virtue of a temporary scheduling order (84
FR 34291, July 18, 2019) and an extension of that order (86 FR 37672,
July 16, 2021). On July 16, 2021, pursuant to 21 U.S.C. 811(a), DEA
published a notice of proposed rulemaking (NPRM) to permanently control
these six synthetic cathinones in schedule I of the CSA. 86 FR 37719.
NPRM
DEA's July 2021 rule proposed to permanently control N-
ethylhexedrone, [alpha]-PHP, 4-MEAP, MPHP, PV8, and 4-chloro-[alpha]-
PVP, and their optical, positional, and geometric isomers, salts, and
salts of isomers in schedule I of the CSA. Specifically, DEA proposed
to add these six synthetic cathinones to the hallucinogenic substances
list under 21 CFR 1308.11(d)(94) through (99), respectively. The
proposed regulatory text provided name(s) for these six substances as
follows:
<bullet> N-ethylhexedrone (other name: [alpha]-
ethylaminohexanophenone),
<bullet> alpha-pyrrolidinohexanophenone (other names: [alpha]-PHP,
[alpha]-pyrrolidino-hexanophenone, 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-
one),
<bullet> 4-methyl-alpha-ethylaminopentiophenone (other names: 4-
MEAP, 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one),
<bullet> 4'-methyl-alpha-pyrrolidinohexiophenone (other names:
MPHP, 4-methyl-alpha-pyrrolidino hexanophenone,, 1-(4-methylphenyl)-2-
(pyrrolidin-1-yl)hexan-1-one),
<bullet> alpha-pyrrolidinoheptaphenone (other names: PV8, 1-phenyl-
2-(pyrrolidin-1-yl)heptan-1-one), and
<bullet> 4'-chloro-alpha-pyrrolidinovalerophenone (other names: 4-
chloro-[alpha]-PVP, 4-chloro-[alpha]-pyrrolidinopentiophenone, 1-(4-
chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one).
Regarding the substance N-ethylhexedrone, the preamble
(Supplementary Information section) for the NPRM provided [alpha]-
ethylaminohexanophenone as well as multiple other names, including 2-
(ethylamino)-1-phenylhexan-1-one.\2\
---------------------------------------------------------------------------
\2\ In addition to [alpha]-ethylaminohexanophenone and 2-
(ethylamino)-1-phenylhexan-1-one, the NPRM preamble provided two
other names (ethyl hexedrone and HEXEN).
---------------------------------------------------------------------------
The NPRM provided an opportunity for interested persons to file a
request for hearing in accordance with DEA regulations on or before
August 16, 2021. No requests for such a hearing were received by DEA.
The NPRM also provided an opportunity for interested persons to submit
comments on the proposed rule on or before August 16, 2021. DEA did not
receive any comments.
Determination for Permanent Scheduling
Based on the rationale set forth in the NPRM, the Administrator
makes the findings, required under 21 U.S.C. 811(a) and 812(b)(1), for
permanent placement of N-ethylhexedrone, [alpha]-PHP, 4-MEAP, MPHP,
PV8, and 4-chloro-[alpha]-PVP, including their salts, isomers, and
salts of isomers whenever the existence of such salts, isomers, and
salts of isomers is possible within the specific chemical designation,
in schedule I of the CSA. This final rule adds the six substances to
the hallucinogenic substances list under 21 CFR 1308.11(d), and
maintains their placement in schedule I. This final rule provides the
same other names for all six specific substances, used in the
regulatory text of the NPRM. In addition, this rule adds one other
name, 2-(ethylamino)-1-phenylhexan-1-one, for the substance N-
ethylhexedrone. As discussed above, this additional other name was
provided in the preamble for the NPRM.
Requirements for Handling N-Ethylhexedrone, [alpha]-PHP, 4-MEAP, MPHP,
PV8, and 4-Chloro-[alpha]-PVP
N-Ethylhexedrone, [alpha]-PHP, 4-MEAP, MPHP, PV8, or 4-chloro-
[alpha]-PVP will continue \3\ to be subject to the CSA's schedule I
regulatory controls and administrative, civil, and criminal sanctions
applicable to the manufacture, distribution, reverse distribution,
importation, exportation, research, and conduct of instructional
activities involving the handling of schedule I controlled substances
including the following:
---------------------------------------------------------------------------
\3\ N-Ethylhexedrone, [alpha]-PHP, 4-MEAP, MPHP, PV8, and 4-
chloro-[alpha]-PVP have been subject to schedule I controls on a
temporary basis, pursuant to 21 U.S.C. 811(h), by virtue of the
temporary scheduling order (84 FR 34291, July 18, 2019) and the
subsequent one year extension of that order (86 FR 37672, July 16,
2021).
---------------------------------------------------------------------------
1. Registration. Any person who handles (manufactures, distributes,
reverse distributes, imports, exports, engages in research, or conducts
instructional activities or chemical analysis with, or possesses) or
who desires to handle N-ethylhexedrone, [alpha]-PHP, 4-MEAP, MPHP, PV8,
or 4-chloro-[alpha]-PVP must be registered with DEA to
[[Page 32998]]
conduct such activities pursuant to 21 U.S.C. 822, 823, 957, and 958,
and in accordance with 21 CFR parts 1301 and 1312.
2. Security. N-Ethylhexedrone, [alpha]-PHP, 4-MEAP, MPHP, PV8, and
4-chloro-[alpha]-PVP are subject to schedule I security requirements
and must be handled and stored pursuant to 21 U.S.C. 823 and in
accordance with 21 CFR 1301.71-1301.76. Non-practitioners handling N-
ethylhexedrone, [alpha]-PHP, 4-MEAP, MPHP, PV8, or 4-chloro-[alpha]-PVP
must also comply with the employee screening requirements of 21 CFR
1301.90-1301.93.
3. Labeling and Packaging. All labels, labeling, and packaging for
commercial containers of N-ethylhexedrone, [alpha]-PHP, 4-MEAP, MPHP,
PV8, and 4-chloro-[alpha]-PVP must be in compliance with 21 U.S.C. 825,
and be in accordance with 21 CFR part 1302.
4. Quota. Only registered manufacturers are permitted to
manufacture N-ethylhexedrone, [alpha]-PHP, 4-MEAP, MPHP, PV8, or 4-
chloro-[alpha]-PVP in accordance with a quota assigned pursuant to 21
U.S.C. 826 and in accordance with 21 CFR part 1303.
5. Inventory. Every DEA registrant who possesses any quantity of N-
ethylhexedrone, [alpha]-PHP, 4-MEAP, MPHP, PV8, or 4-chloro-[alpha]-PVP
was required to keep an inventory of all stocks of these substances on
hand as of July 18, 2019, pursuant to 21 U.S.C. 827 and 958 and in
accordance with 21 CFR 1304.03, 1304.04, and 1304.11(a) and (d).
6. Records and Reports. DEA registrants must maintain records and
submit reports with respect to N-ethylhexedrone, [alpha]-PHP, 4-MEAP,
MPHP, PV8, or 4-chloro-[alpha]-PVP pursuant to 21 U.S.C. 827 and
958(e), and in accordance with 21 CFR 1301.74(b) and (c) and parts
1304, 1312, and 1317. Manufacturers and distributors must submit
reports regarding these substances to the Automation of Reports and
Consolidated Order System pursuant to 21 U.S.C. 827 and in accordance
with 21 CFR parts 1304 and 1312.
7. Order Forms. Every DEA registrant who distributes N-
ethylhexedrone, [alpha]-PHP, 4-MEAP, MPHP, PV8, or 4-chloro-[alpha]-PVP
must continue to comply with the order form requirements, pursuant to
21 U.S.C. 828 and in accordance with 21 CFR part 1305.
8. Importation and Exportation. All importation and exportation of
N-ethylhexedrone, [alpha]-PHP, 4-MEAP, MPHP, PV8, or 4-chloro-[alpha]-
PVP must continue to be in compliance with 21 U.S.C. 952, 953, 957, and
958, and in accordance with 21 CFR part 1312.
9. Liability. Any activity involving N-ethylhexedrone, [alpha]-PHP,
4-MEAP, MPHP, PV8, or 4-chloro-[alpha]-PVP not authorized by, or in
violation of the CSA or its implementing regulations, is unlawful, and
may subject the person to administrative, civil, and/or criminal
sanctions.
Regulatory Analyses
Executive Orders 12866 (Regulatory Planning and Review) and 13563
(Improving Regulation and Regulatory Review)
In accordance with 21 U.S.C. 811(a), this scheduling action is
subject to formal rulemaking procedures performed ``on the record after
opportunity for a hearing,'' which are conducted pursuant to the
provisions of 5 U.S.C. 556 and 557. The CSA sets forth the criteria for
scheduling a drug or other substance. Such actions are exempt from
review by the Office of Management and Budget (OMB) pursuant to section
3(d)(1) of Executive Order (E.O.) 12866 and the principles reaffirmed
in E.O. 13563.
Executive Order 12988, Civil Justice Reform
This regulation meets the applicable standards set forth in
sections 3(a) and 3(b)(2) of E.O. 12988 to eliminate drafting errors
and ambiguity, minimize litigation, provide a clear legal standard for
affected conduct, and promote simplification and burden reduction.
Executive Order 13132, Federalism
This rulemaking does not have federalism implications warranting
the application of E.O. 13132. The final rule does not have substantial
direct effects on the states, on the relationship between the national
government and the states, or the distribution of power and
responsibilities among the various levels of government.
Executive Order 13175, Consultation and Coordination With Indian Tribal
Governments
This final rule does not have tribal implications warranting the
application of E.O. 13175. It does not have substantial direct effects
on one or more Indian tribes, on the relationship between the Federal
government and Indian tribes, or on the distribution of power and
responsibilities between the Federal government and Indian tribes.
Regulatory Flexibility Act
The Administrator, in accordance with the Regulatory Flexibility
Act, 5 U.S.C. 601-612, has reviewed this final rule and by approving it
certifies that it will not have a significant economic impact on a
substantial number of small entities. On July 18, 2019, DEA published
an order to temporarily place N-ethylhexedrone, [alpha]-PHP, 4-MEAP,
MPHP, PV8, and 4-chloro-[alpha]-PVP in schedule I of the CSA pursuant
to the temporary scheduling provisions of 21 U.S.C. 811(h). 84 FR
34291. DEA estimates that all entities handling or planning to handle
these substances have already established and implemented the systems
and processes required to handle N-ethylhexedrone, [alpha]-PHP, 4-MEAP,
MPHP, PV8, or 4-chloro-[alpha]-PVP. There are currently 34 unique
registrations authorized to handle N-ethylhexedrone, [alpha]-PHP, 4-
MEAP, MPHP, PV8, or 4-chloro-[alpha]-PVP specifically, as well as a
number of registered analytical labs that are authorized to handle
schedule I controlled substances generally. From review of entity
names, DEA estimates these 34 registrations represent 29 entities. Some
of these entities are likely to be large entities. However, since DEA
does not have information of registrant size and the majority of DEA
registrants are small entities or are employed by small entities, DEA
estimates a maximum of 29 entities are small entities. Therefore, DEA
conservatively estimates as many as 29 small entities are affected by
this proposed rule.
A review of the 34 registrations indicates that all entities that
currently handle N-ethylhexedrone, [alpha]-PHP, 4-MEAP, MPHP, PV8, or
4-chloro-[alpha]-PVP also handle other schedule I controlled
substances, and thus they have established and implemented (or
maintain) the systems and processes required to handle N-
ethylhexedrone, [alpha]-PHP, 4-MEAP, MPHP, PV8, and 4-chloro-[alpha]-
PVP as a schedule I substance. Therefore, DEA anticipates that this
final rule will impose minimal or no economic impact on any affected
entities, and, thus, will not have a significant economic impact on any
of the 29 affected small entities. Therefore, DEA has concluded that
this final rule will not have a significant economic impact on a
substantial number of small entities.
Unfunded Mandates Reform Act of 1995
In accordance with the Unfunded Mandates Reform Act (UMRA) of 1995,
2 U.S.C. 1501 et seq., DEA has determined and certifies that this
action would not result in any Federal mandate that may result ``in the
expenditure by State, local, and tribal governments, in the aggregate,
or by the private sector, of $100,000,000 or more (adjusted annually
for inflation) in any 1 year * * * .'' Therefore, neither a Small
Government Agency Plan nor any
[[Page 32999]]
other action is required under UMRA of 1995.
Congressional Review Act
This rule is not a major rule as defined by the Congressional
Review Act (CRA), 5 U.S.C. 804. However, pursuant to the CRA, DEA is
submitting a copy of the final rule to both Houses of Congress and to
the Comptroller General.
Paperwork Reduction Act of 1995
This action does not impose a new collection of information under
the Paperwork Reduction Act of 1995. 44 U.S.C. 3501-3521. This action
would not impose recordkeeping or reporting requirements on State or
local governments, individuals, businesses, or organizations. An agency
may not conduct or sponsor, and a person is not required to respond to,
a collection of information unless it displays a currently valid OMB
control number.
Determination To Make Rule Effective Immediately
As indicated above, this rule finalizes the schedule I control
status of N-ethylhexedrone, [alpha]-PHP, 4-MEAP, MPHP, PV8, and 4-
chloro-[alpha]-PVP that has already been in effect for over two years
by virtue of the temporary scheduling order (84 FR 34291, July 18,
2019) and the subsequent one year extension of that order (86 FR 37672,
July 16, 2021). The July 2019 order was effective on the date of
publication, and was based on findings by the then-Acting Administrator
that the temporary scheduling of these substances was necessary to
avoid an imminent hazard to the public safety pursuant to 21 U.S.C.
811(h)(1).
Because this rule finalizes the control status of N-ethylhexedrone,
[alpha]-PHP, 4-MEAP, MPHP, PV8, and 4-chloro-[alpha]-PVP that has
already been in effect for over two years, it does not alter the legal
obligations of any person who handles these substances. Rather, it
merely makes permanent the current scheduling status and corresponding
legal obligations. Therefore, DEA is making the rule effective on the
date of publication in the Federal Register, as any delay in the
effective date is unnecessary and would be contrary to the public
interest. See 5 U.S.C. 553(d).
List of Subjects in 21 CFR Part 1308
Administrative practice and procedure, Drug traffic control,
Reporting and recordkeeping requirements.
For the reasons set out above, DEA amends 21 CFR part 1308 as
follows:
PART 1308--SCHEDULES OF CONTROLLED SUBSTANCES
0
1. The authority citation for part 1308 continues to read as follows:
Authority: 21 U.S.C. 811, 812, 871(b), 956(b), unless otherwise
noted.
0
2. In Sec. 1308.11, add paragraphs (d)(94) through (99) and remove and
reserve paragraphs (h)(42) through (47).
The additions read as follows:
Sec. 1308.11 Schedule I.
* * * * *
(d) * * *
(94) N-Ethylhexedrone (Other names: [alpha]- 7246
ethylaminohexanophenone; 2-(ethylamino)-1-phenylhexan-1-
one)...................................................
(95) alpha-Pyrrolidinohexanophenone (Other names: 7544
[alpha]-PHP; [alpha]-pyrrolidinohexanophenone; 1-phenyl-
2-(pyrrolidin-1-yl)hexan-1-one)........................
(96) 4-Methyl-alpha-ethylaminopentiophenone (Other 7245
names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-
1-one).................................................
(97) 4'-Methyl-alpha-pyrrolidinohexiophenone (Other 7446
names: MPHP; 4'-methyl-alpha-pyrrolidinohexanophenone;
1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one).....
(98) alpha-Pyrrolidinoheptaphenone (Other names: PV8; 1- 7548
phenyl-2-(pyrrolidin-1-yl)heptan-1-one)................
(99) 4'-Chloro-alpha-pyrrolidinovalerophenone (Other 7443
names: 4-chloro-[alpha]-PVP; 4'-chloro-[alpha]-
pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-
(pyrrolidin-1-yl)pentan-1-one).........................
* * * * *
Anne Milgram,
Administrator.
[FR Doc. 2022-11740 Filed 5-31-22; 8:45 am]
BILLING CODE 4410-09-P
</pre></body>
</html>Indexed from Federal Register on June 1, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.